Featured Publications
Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients
Baraban E, Hu S, Hui P, Podoltsev N, Cooper D, Xu M. Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients. Bone Marrow Transplantation 2016, 52: 634-637. PMID: 27991892, DOI: 10.1038/bmt.2016.332.Peer-Reviewed Original ResearchExpression of CD30 as a biomarker to predict response to brentuximab vedotin
Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.Peer-Reviewed Original Research
2022
Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics
Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.Peer-Reviewed Original ResearchConceptsLarge B-cell lymphomaDistinct clinicopathologic characteristicsMedian overall survivalB-cell lymphomaOverall survivalClinicopathologic characteristicsPrimary effusion lymphomaHHV8 infectionLymphomatous effusionsNon-germinal center B-cell subtypeLonger median overall survivalUnique clinicopathologic characteristicsFavorable prognostic factorEpstein-Barr virusSeparate diagnostic criteriaHuman herpesvirus 8B-cell subtypeMulti-institutional studyNon-Japanese casesDiagnostic uniformityImmunocompetent patientsPericardial effusionPericardial involvementSelect patientsChemotherapy administration
2021
Coronavirus Disease 2019 (COVID-19) Coronary Vascular Thrombosis Correlation with Neutrophil but Not Endothelial Activation
Johnson JE, McGuone D, Xu ML, Jane-Wit D, Mitchell RN, Libby P, Pober JS. Coronavirus Disease 2019 (COVID-19) Coronary Vascular Thrombosis Correlation with Neutrophil but Not Endothelial Activation. American Journal Of Pathology 2021, 192: 112-120. PMID: 34599881, PMCID: PMC8479934, DOI: 10.1016/j.ajpath.2021.09.004.Peer-Reviewed Original ResearchConceptsVascular cell adhesion molecule-1Intracellular adhesion molecule-1Adhesion molecule-1Von Willebrand factorEndothelial activationMolecule-1Severe coronavirus disease 2019Neutrophil extracellular trap formationCell adhesion molecule-1COVID-19 cohortCOVID-19 patientsNeutrophil-platelet aggregatesCoronavirus disease 2019Extracellular trap formationCOVID-19Transcription factor p65Extensive thrombosisLymphocytic infiltrationMyocardial injuryThrombotic diathesisInflammatory activationNeutrophil activationCardiovascular diseaseDisease 2019Autopsy tissueSecondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients
Gru AA, Bacchi CE, Pulitzer M, Bhagat G, Kempf W, Robson A, Plaza JA, Pincus L, Raghavan S, Xu M, da Silva T, Salavaggione AL, Subtil A, Battistella M. Secondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients. Journal Of Cutaneous Pathology 2021, 48: 1367-1378. PMID: 34089205, PMCID: PMC9555338, DOI: 10.1111/cup.14077.Peer-Reviewed Original ResearchConceptsClassic Hodgkin lymphomaSecondary skin involvementHodgkin's lymphomaCutaneous involvementSkin involvementComprehensive histopathologic evaluationStage IV diseaseNodular sclerosis typeLarge case seriesBoard-certified dermatopathologistClassic HLSkin disseminationMixed cellularityMost patientsCase seriesSclerosis typeImmunophenotypic featuresInfiltrative plaquesFirst diagnosisHistopathologic evaluationMultiple lesionsSkin lesionsSingle lesionLarge seriesClinical diagnosisIRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias
Katz SG, Edappallath S, Xu ML. IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias. The American Journal Of Surgical Pathology 2021, 45: 1391-1398. PMID: 34172624, DOI: 10.1097/pas.0000000000001765.Peer-Reviewed Original ResearchConceptsChronic myelomonocytic leukemiaAcute monocytic leukemiaBlast countCore biopsyMyelomonocytic leukemiaBone marrowPredictive valueMonocytic leukemiaBone marrow core biopsiesCases of AMoLMarrow core biopsiesAcute myeloid leukemia subtypesExpression of IRF8Acute myeloid leukemiaTrephine core biopsiesReliable surface markersDendritic cell progenitorsNegative predictive valuePositive predictive valuePotential biomarker candidatesBlast increaseMonocytic blastsUseful immunostainsBlast percentageReactive monocytosisClinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group
Weinberg OK, Chisholm KM, Ok CY, Fedoriw Y, Grzywacz B, Kurzer JH, Mason EF, Moser KA, Bhattacharya S, Xu M, Babu D, Foucar K, Tam W, Bagg A, Orazi A, George TI, Wang W, Wang SA, Arber DA, Hasserjian RP. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology 2021, 34: 1358-1366. PMID: 33526873, DOI: 10.1038/s41379-021-00739-4.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAcute undifferentiated leukemiaWhite blood cellsLymphoblastic leukemiaAcute leukemiaBone Marrow Pathology GroupHigher white blood cellEvent-free survivalNatural killer cellsClinical outcome dataNative immune systemMore frequent expressionAUL patientsFree survivalAmbiguous lineageOverall survivalCytoplasmic CD3Leukemia groupClinical presentationHLA-DRKiller cellsPlatelet countProvisional entityCD10 expressionMyeloid leukemia
2020
Cutaneous Involvement in Plasma Cell Myeloma
Panse G, Subtil A, McNiff JM, Glusac EJ, Ko CJ, Galan A, Myung P, Xu ML. Cutaneous Involvement in Plasma Cell Myeloma. American Journal Of Clinical Pathology 2020, 155: 106-116. PMID: 32885235, DOI: 10.1093/ajcp/aqaa122.Peer-Reviewed Original ResearchConceptsPlasma cell myelomaCutaneous involvementSquamous cell carcinomaAmyloid depositionCell carcinomaCell myelomaCases of PCMBone marrow involvementCyclin D1 immunoreactivityDisease-related deathLight chain restrictionCCND1 gene rearrangementMarrow involvementSkin involvementClinicopathologic featuresCytomorphologic spectrumCutaneous lesionsPoor outcomeCommon immunophenotypeChain restrictionClinical dataCytogenetic findingsOlder individualsGene rearrangementsMyelomaGlucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy
Nair S, Bar N, Xu ML, Dhodapkar M, Mistry PK. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Molecular Genetics And Metabolism 2020, 129: 286-291. PMID: 32044242, PMCID: PMC8223251, DOI: 10.1016/j.ymgme.2020.01.009.Peer-Reviewed Original ResearchConceptsGaucher disease type 1Monoclonal gammopathyAntigenic targetsClonal immunoglobulinDisease type 1B cell activationAccumulation of glucosylceramideGD1 patientsImmunogenic lipidsMetabolic inflammationMultiple myelomaGD patientsHigh riskTarget antigenCell activationImmunoglobulin typeGammopathyType 1PatientsGenetic deficiencyAge-related phenotypesSaposin CClonal IgLysosomal glucocerebrosidaseGlcSphDisseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia
Shallis RM, Patel TH, Podoltsev NA, Xu ML, Azar MM, Gore SD. Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia. Leukemia Research 2020, 90: 106315. PMID: 32036123, DOI: 10.1016/j.leukres.2020.106315.Peer-Reviewed Case Reports and Technical Notes
2019
Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma
Wang JD, Katz SG, Morgan EA, Yang DT, Pan X, Xu ML. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. Human Pathology 2019, 93: 54-64. PMID: 31425695, PMCID: PMC7038910, DOI: 10.1016/j.humpath.2019.08.008.Peer-Reviewed Original ResearchConceptsMantle cell lymphomaCell lymphomaAnn Arbor stage IIINovel independent prognostic factorAggressive B-cell lymphomasHigh Bim expressionAverage patient ageBim expressionIndependent prognostic factorLarge academic medical centerKi-67 indexNovel prognostic markerB-cell lymphomaAcademic medical centerCyclin D1 overexpressionHuman mantle cell lymphomaMCL cohortMIPI scoreProgressive diseaseComplete responseOverall survivalPatient agePrognostic factorsTumor cell survivalFemale ratioPhiladelphia chromosome‐negative acute leukemia in patients with chronic myeloid leukemia
Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S. Philadelphia chromosome‐negative acute leukemia in patients with chronic myeloid leukemia. American Journal Of Hematology 2019, 94: e256-e259. PMID: 31273842, DOI: 10.1002/ajh.25571.Peer-Reviewed Original ResearchAbnormal KaryotypeAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBlast CrisisBone MarrowChromosome AberrationsDiagnosis, DifferentialDiagnostic ErrorsFemaleFollow-Up StudiesHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesNeoplasms, Second PrimaryPhiladelphia ChromosomeRetrospective StudiesYoung AdultClinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx
Chen PH, Yang Y, O'Malley DP, Xu ML. Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx. Annals Of Diagnostic Pathology 2019, 41: 129-135. PMID: 31247533, DOI: 10.1016/j.anndiagpath.2019.06.007.Peer-Reviewed Original ResearchConceptsB-cell non-Hodgkin lymphomaEBV-negative casesAggressive B-NHLPD-L1Peptide receptor radionuclide therapyAggressive B-cell lymphomasEBV-positive DLBCLEBV-positive patientsDisease-free intervalPrimary clinical outcomeYear of diagnosisEBV-positive casesReceptor radionuclide therapyExpression of SSTR2Non-Hodgkin lymphomaExpression of CD30Five yearsAvailable outcome dataB-cell lymphomaEBV negativityInitial therapyClinicopathologic characteristicsBetter prognosisCase seriesClinical outcomesMantle Cell Lymphoma With Mantle Zone Growth Pattern
Yuan J, Li S, Liu X, Su RJ, Chen M, Wu X, Zheng G, Smith LM, Wang L, Li Y, Liu C, Zhou J, Shen Q, Zhang L, Wang E, Xu ML, Pan Z. Mantle Cell Lymphoma With Mantle Zone Growth Pattern. American Journal Of Clinical Pathology 2019, 152: 132-145. PMID: 31140550, DOI: 10.1093/ajcp/aqz043.Peer-Reviewed Original ResearchConceptsMantle zone growth patternMantle cell lymphomaCell lymphomaHigher clinical stageOverall survivalPathologic featuresClinicopathologic dataClinical stageSuspicious morphologyClinical significanceCyclin D1Lymphoma cellsCell cytologyGrowth patternSignificant differencesPatientsLymphomaChemotherapyLymphCD5ImmunostainsCytologyCasesClinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, Xu ML, Prebet T, Mason EF, Seegmiller AC, Morgan EA, Steensma DP, Winer ES, Wong WJ, Hasserjian RP, Weinberg OK. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Advances 2019, 3: 1540-1545. PMID: 31085507, PMCID: PMC6517660, DOI: 10.1182/bloodadvances.2019000090.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AFemaleHumansMaleMiddle AgedMutationMyelodysplastic SyndromesNuclear ProteinsNucleophosminPrognosisProportional Hazards ModelsProtein Tyrosine Phosphatase, Non-Receptor Type 11Survival RateTumor Suppressor Protein p53ConceptsMyelodysplastic syndromeMyeloid neoplasmsDe novo acute myeloid leukemia (AML) patientsNovo acute myeloid leukemia patientsAcute myeloid leukemia patientsBone marrow blastsAggressive clinical courseStem cell transplantLimited case seriesShorter overall survivalMyeloid leukemia patientsIntensive therapeutic regimensTotal mutation countsMarrow blastsOverall survivalClinical courseCase seriesCell transplantMultivariable analysisTherapeutic regimensLeukemia patientsLarge cohortYounger agePatientsNormal karyotype
2018
Conviction in the face of affliction: a case series of Jehovah’s Witnesses with myeloid malignancies
Shallis RM, Xu ML, Curtis SA, Medoff E, Mixon R, Folkers A, Zeidan AM. Conviction in the face of affliction: a case series of Jehovah’s Witnesses with myeloid malignancies. Annals Of Hematology 2018, 97: 2245-2248. PMID: 30088044, DOI: 10.1007/s00277-018-3459-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPatients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses
Romberg N, Le Coz C, Glauzy S, Schickel JN, Trofa M, Nolan BE, Paessler M, Xu M, Lambert MP, Lakhani SA, Khokha MK, Jyonouchi S, Heimall J, Takach P, Maglione PJ, Catanzaro J, Hsu FI, Sullivan KE, Cunningham-Rundles C, Meffre E. Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses. Journal Of Allergy And Clinical Immunology 2018, 143: 258-265. PMID: 29935219, PMCID: PMC6400323, DOI: 10.1016/j.jaci.2018.06.012.Peer-Reviewed Original ResearchConceptsCommon variable immunodeficiencyVariable immunodeficiencyB cellsCommensal bacteriaIsotype-switched memory B cellsRegulatory T cell frequencyFollicular helper T cellsGC responseIsotype-switched antibodiesT cell frequenciesSubset of patientsT cell compartmentHelper T cellsPeripheral blood samplesMemory B cellsGerminal center responseB cell clonesAutoimmune cytopeniasGC hyperplasiaSerum endotoxemiaExcisional lymphAntibody responseT cellsMucosal microbiotaSomatic hypermutation frequenciesSmall Cell Variant of Intravascular Large B‐Cell Lymphoma: Highlighting a Potentially Fatal and Easily Missed Diagnosis
Rahmani M, Halene S, Xu ML. Small Cell Variant of Intravascular Large B‐Cell Lymphoma: Highlighting a Potentially Fatal and Easily Missed Diagnosis. BioMed Research International 2018, 2018: 9413015. PMID: 29850589, PMCID: PMC5903319, DOI: 10.1155/2018/9413015.Peer-Reviewed Case Reports and Technical NotesConceptsIntravascular large B-cell lymphomaB-cell lymphomaLarge B-cell lymphomaSmall cell morphologySmall cell variantCases of IVLBCLCell variantHodgkin's B-cell lymphomaRandom skin biopsySmall bowel biopsyHigh clinical suspicionLarge atypical cellsSmall cell lymphomaSmall blood vesselsBowel biopsyClinical suspicionLymph nodesRetrospective reviewClinicopathologic featuresSmall bowelPoor prognosisAtypical cellsFallopian tubeSkin biopsiesDifferential diagnosis
2016
Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia
Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Annals Of Hematology 2016, 95: 1197-1200. PMID: 27068405, PMCID: PMC7479634, DOI: 10.1007/s00277-016-2664-4.Peer-Reviewed Original Research
2015
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary
Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary. Oncotarget 2015, 6: 13933-13945. PMID: 26101854, PMCID: PMC4546442, DOI: 10.18632/oncotarget.4324.Peer-Reviewed Original ResearchConceptsEpstein-Barr virus-positive diffuse large B-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaYears of ageFrequent expressionOlder patientsAge cutoffMonoclonal B-cell proliferationArbitrary age cutoffsPoor performance statusGenetic featuresMore frequent expressionB cell proliferationPerformance statusYounger patientsClinicopathologic evidencePatient groupDLBCL patientsTreatment outcomesPatientsDLBCLGene expression profilingCD30Lymphoma